PDF(Pubmed)
Abstract：
BACKGROUND: Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning of future preventative actions to reduce HTLV-1 infection and its consequences would be essential.
METHODS: MEDLINE, Scopus, Web of Science, and Clinicaltrials.gov were searched from each database\'s inception through March 27, 2022. All original articles focusing on developing an HTLV-1 vaccine candidate were included.
RESULTS: A total of 47 studies were included. They used a variety of approaches to develop the HTLV-1 vaccine, including DNA-based, dendritic-cell-based, peptide/protein-based, and recombinant vaccinia virus approaches. The majority of the research that was included utilized Tax, Glycoprotein (GP), GAG, POL, REX, and HBZ as their main peptides in order to develop the vaccine. The immunization used in dendritic cell-based investigations, which were more recently published, was accomplished by an activated CD-8 T-cell response. Although there hasn\'t been much attention lately on this form of the vaccine, the initial attempts to develop an HTLV-1 immunization depended on recombinant vaccinia virus, and the majority of results seem positive and effective for this type of vaccine. Few studies were conducted on humans. Most of the studies were experimental studies using animal models. Adenovirus, Cytomegalovirus (CMV), vaccinia, baculovirus, hepatitis B, measles, and pox were the most commonly used vectors.
CONCLUSIONS: This systematic review reported recent progression in the development of HTLV-1 vaccines to identify candidates with the most promising preventive and therapeutic effects.
METHODS: MEDLINE, Scopus, Web of Science, and Clinicaltrials.gov were searched from each database\'s inception through March 27, 2022. All original articles focusing on developing an HTLV-1 vaccine candidate were included.
RESULTS: A total of 47 studies were included. They used a variety of approaches to develop the HTLV-1 vaccine, including DNA-based, dendritic-cell-based, peptide/protein-based, and recombinant vaccinia virus approaches. The majority of the research that was included utilized Tax, Glycoprotein (GP), GAG, POL, REX, and HBZ as their main peptides in order to develop the vaccine. The immunization used in dendritic cell-based investigations, which were more recently published, was accomplished by an activated CD-8 T-cell response. Although there hasn\'t been much attention lately on this form of the vaccine, the initial attempts to develop an HTLV-1 immunization depended on recombinant vaccinia virus, and the majority of results seem positive and effective for this type of vaccine. Few studies were conducted on humans. Most of the studies were experimental studies using animal models. Adenovirus, Cytomegalovirus (CMV), vaccinia, baculovirus, hepatitis B, measles, and pox were the most commonly used vectors.
CONCLUSIONS: This systematic review reported recent progression in the development of HTLV-1 vaccines to identify candidates with the most promising preventive and therapeutic effects.
摘要：
背景：已经在非灵长类宿主上进行了许多疫苗接种研究实验，以预防或控制HTLV-1感染。因此,回顾最近的进展状态评估和未来预防行动的战略规划，以减少HTLV-1感染及其后果将是至关重要的。
方法：MEDLINE，Scopus,WebofScience,和Clinicaltrials.gov从每个数据库的开始搜索到2022年3月27日。包括所有专注于开发HTLV-1候选疫苗的原始文章。
结果：共纳入47项研究。他们使用了多种方法来开发HTLV-1疫苗，包括基于DNA的，基于树突状细胞，基于肽/蛋白质，和重组牛痘病毒方法。包括在内的大多数研究都是利用税收，糖蛋白（GP），GAG,POL,雷克斯,和HBZ作为它们的主要肽以开发疫苗。在基于树突状细胞的研究中使用的免疫，最近出版的，是通过激活的CD-8T细胞应答完成的。尽管最近对这种形式的疫苗没有太多关注，开发HTLV-1免疫的最初尝试依赖于重组痘苗病毒，对于这种疫苗，大多数结果似乎是积极和有效的。很少对人类进行研究。大多数研究是使用动物模型的实验研究。腺病毒,巨细胞病毒(CMV),牛痘,杆状病毒,乙型肝炎，麻疹,痘痘是最常用的载体。
结论：本系统综述报告了开发HTLV-1疫苗的最新进展，以确定具有最有希望的预防和治疗效果的候选疫苗。
方法：MEDLINE，Scopus,WebofScience,和Clinicaltrials.gov从每个数据库的开始搜索到2022年3月27日。包括所有专注于开发HTLV-1候选疫苗的原始文章。
结果：共纳入47项研究。他们使用了多种方法来开发HTLV-1疫苗，包括基于DNA的，基于树突状细胞，基于肽/蛋白质，和重组牛痘病毒方法。包括在内的大多数研究都是利用税收，糖蛋白（GP），GAG,POL,雷克斯,和HBZ作为它们的主要肽以开发疫苗。在基于树突状细胞的研究中使用的免疫，最近出版的，是通过激活的CD-8T细胞应答完成的。尽管最近对这种形式的疫苗没有太多关注，开发HTLV-1免疫的最初尝试依赖于重组痘苗病毒，对于这种疫苗，大多数结果似乎是积极和有效的。很少对人类进行研究。大多数研究是使用动物模型的实验研究。腺病毒,巨细胞病毒(CMV),牛痘,杆状病毒,乙型肝炎，麻疹,痘痘是最常用的载体。
结论：本系统综述报告了开发HTLV-1疫苗的最新进展，以确定具有最有希望的预防和治疗效果的候选疫苗。
